Tetra Bio-Pharma Inc. - TBPMF STOCK NEWS

Tetra Bio-Pharma announced that its Dronabinol Soft Gel capsules New Drug Submission (NDS) has successfully cleared the screening phase with Health Canada. This marks a significant step towards obtaining Canada's first Drug Identification Number (DIN) for a THC-based prescription drug, Reduvo™. The addressable market in Canada is estimated at $80M CDN by 2022. Tetra anticipates launching Reduvo™ in the second half of 2021, establishing a revenue stream for treating chemotherapy-induced nausea and vomiting. The company aims for public reimbursement through an aggressive market access strategy.

Tetra Bio-Pharma (OTCQB: TBPMF) issued a correction regarding its February 25, 2021 news release. The reported estimate for peak sales by 2026 attributed to DanCann Pharma's CCO John Morell Frellsen was incorrectly stated as 55 million DKK. The accurate figure is 55 million USD. Tetra Bio-Pharma focuses on developing immunomodulator drugs and has a clinical program approved by both the FDA and Health Canada, aimed at addressing various medical conditions.

Tetra Bio-Pharma (TSX:TBP, OTCQB:TBPMF) has announced that CEO Dr. Guy Chamberland will present a company overview during the H.C. Wainwright Global Life Sciences Virtual Conference on March 9-10, 2021. Investors can register for the event here. The presentation will be available for on-demand viewing starting March 9, 2021, at 7:00 AM ET. The company focuses on developing immunomodulator drugs for various conditions, emphasizing scientific validation and safety.

Tetra Bio-Pharma has signed a Letter of Intent with DanCann Pharma for exclusive distribution of Reduvo™ Adversa®, QIXLEEF™, and ENJOUCA™ in Denmark, Norway, Sweden, Finland, and Germany. Pending registration with the European Medicines Agency (EMA), DanCann will manage sales and distribution. The agreement includes upfront and milestone payments of up to $2.25M CDN and a confidential royalty on net sales. Notably, Reduvo™ Adversa® is designed for chemotherapy-induced nausea and vomiting and offers enhanced bioavailability. The revenue potential is estimated at 55M DKK by 2026.

Tetra Bio-Pharma estimates potential net sales of $675 million USD by 2027 for its cannabinoid-derived medicine, QIXLEEF™, aimed at advanced cancer patients with pain. The company is seeking commercial partners for its U.S. launch and anticipates FDA market approval in late 2023 following the completion of the Phase II trial in 2021 and Phase III in early 2022. The revenue forecast remains conservative and does not account for potential additional uses.

Tetra Bio-Pharma announced significant advancements in its cannabinoid drug programs, including the initiation of the Reborn trial aimed at reducing opioid use and the successful mapping of cannabinoid metabolites.

The company achieved key milestones for its COVID-19 drug ARDS-003, including the completion of necessary toxicology studies and the development of a sterile injectable formulation.

Tetra has partnered with a U.S. manufacturer to ensure the production of CAUMZ for upcoming clinical trials and continues its efforts toward securing marketing approvals for its drug products.

Tetra Bio-Pharma Inc. (TBPMF) has announced potential revenues exceeding $500 million by 2026 from its new drug ARDS-003, targeting COVID-19 related conditions. This drug aims to provide survival benefits while being a cost-saving alternative alongside standard treatments like Remdesivir™. ARDS-003 is not a vaccine but a therapeutic solution for severe inflammatory responses, with further market potential in sepsis-related indications. Tetra emphasizes an extensive market opportunity given the rising incidence of sepsis globally, which was linked to 11 million deaths in 2017.

Tetra Bio-Pharma has finalized the divestiture of its subsidiary, Lumiera Health Innovation, to Mondias Natural Products for CAN$1.3 million in stock. The transaction involved a share exchange of 16,250,000 Mondias shares. Additionally, a CAN$2 million convertible debt facility has been amended to a CAN$3 million non-convertible debt facility with a 15% annual interest rate, guaranteed by Tetra's shares from the transaction. The maturity date for the amended note is set for February 27, 2022.

Tetra Bio-Pharma has entered a research collaboration with Targeted Pharmaceutical and George Mason University's NCBID to evaluate ARDS-003 in SARS-CoV-2 infected animals. This partnership aims to explore ARDS-003's potential as a therapeutic agent against COVID-19. Tetra has obtained a 20% minority stake in Targeted Pharmaceutical, enhancing its research capabilities. The project will be led by Dr. Lance Liotta, providing significant insights into the drug's role in modulating cytokine release during COVID-19 infection.